title: Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: results of the anistreplase reocclusion multicenter study (ARMS).
abstract: In this open multicenter study, 156 patients with acute myocardial infarction received 30 U of anistreplase intravenously over 5 minutes within 4 hours of the onset of chest pain. The patency of the infarct-related vessel was determined by coronary angiography 90 minutes after anistreplase treatment, and also 24 hours after treatment, in patients with a patent infarct-related vessel at 90 minutes, to assess the reocclusion rate. The investigators categorized the infarct-related vessel as patent or occluded, and 2 independent cardiologists graded the infarct-related vessel according to the Thrombolysis in Myocardial Infarction (TIMI) perfusion criteria. At the 90-minute assessment, 106 of 145 evaluable patients (73%) had patent infarct-related vessels, and 39 of 145 (27%) had occluded infarct-related vessels. Of the 139 independently assessed patients, 98 (71%) had TIMI grades 2 or 3 and 41 (29%) had TIMI grades 0 or 1. At the 24-hour assessment, 98 of 102 patients (96%) had a patent infarct-related vessel, and reocclusion had occurred in 4 of 102 patients (4%). Of the 94 independently assessed patients 90 (96%) had TIMI grades 2 or 3, and 4 (4%) had TIMI grades 0 or 1. The reliability of noninvasive parameters as indicators of achieved patency of the infarct-related vessel was estimated by means of correlation with patency assessed by coronary angiography. A significant correlation of 0.62 was found. The patency rate of 71 to 73% after use of anistreplase in patients with acute myocardial infarction corresponds with findings in earlier studies. The low reocclusion rate of 4% after use of anistreplase probably reflects the prolonged action of anistreplase.
authors.affiliation: Department of Cardiology, Deaconesses Hospital, Eindhoven, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: Relik-van Wely
authors.forename: R F
authors.initials: RF
authors.lastname: Visser
authors.forename: J M
authors.initials: JM
authors.lastname: van der Pol
authors.forename: I
authors.initials: I
authors.lastname: Bartholomeus
authors.forename: J E
authors.initials: JE
authors.lastname: Couvée
authors.forename: H
authors.initials: H
authors.lastname: Drost
authors.forename: A J
authors.initials: AJ
authors.lastname: Vet
authors.forename: H C
authors.initials: HC
authors.lastname: Klomps
authors.forename: W A
authors.initials: WA
authors.lastname: van Ekelen
authors.forename: F
authors.initials: F
authors.lastname: van den Berg
mesh_terms: D000328:Adult; D000368:Aged; D016255:Anistreplase / Q000009:adverse effects / Q000627:therapeutic use*; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology; D012008:Recurrence; D015912:Thrombolytic Therapy; D013997:Time Factors; D014654:Vascular Patency / Q000187:drug effects*
chemical_list: D007527:Isoenzymes; D016255:Anistreplase; D003402:Creatine Kinase